An Assessment of the Management of Acute Bleeding Varices: A Multicenter Prospective Member-Based Study

American Journal of Gastroenterology

Volumn 98, Issue 11, 2003, Pages 2424-2434

  Sorbi, Darius ^b   Gostout, Christopher J ^a   Peura, David ^b   Johnson, David ^b   Lanza, Frank ^b   Foutch, P Gregory ^b   Schleck, Cathy D ^b   Zinsmeister, Alan R ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYANOACRYLATE; ETHANOLAMINE DERIVATIVE; FRESH FROZEN PLASMA; HISTAMINE H2 RECEPTOR ANTAGONIST; MORRHUATE SODIUM; NITRIC ACID DERIVATIVE; OCTREOTIDE; POLIDOCANOL; PROTON PUMP INHIBITOR; SCLEROSING AGENT; SUCRALFATE; TETRADECYL SULFATE SODIUM; VASOPRESSIN;

ADULT; ALCOHOL ABUSE; ARTICLE; ARTIFICIAL EMBOLISM; ASPIRATION PNEUMONIA; BALLOON CATHETER; BLOOD TRANSFUSION; BRAIN DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DYSPHAGIA; ENDOSCOPIC THERAPY; ERYTHROCYTE TRANSFUSION; ESOPHAGUS VARICES BLEEDING; FEMALE; GASTROENTEROLOGY; HEMODYNAMICS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATORENAL SYNDROME; HUMAN; INFORMATION PROCESSING; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORTHOSTATIC HYPOTENSION; PHYSICIAN; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESEARCH; SCLEROTHERAPY; SIDE EFFECT; SWALLOWING; TACHYCARDIA; THROMBOCYTE; TRAINING; TREATMENT OUTCOME; ULCER;

EID: 0345358680     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.t01-1-07705.x     Document Type: Article

References (97)

1. Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 2001;96:3039-40.
2. McKiernan PJ. Treatment of variceal bleeding. Gastrointest Endosc Clin North Am 2001;11:789-812.
3. Lowe RC, Grace ND. Primary prophylaxis of variceal hemorrhage. Clin Liver Dis 2001;5:665-76.
4. Gostout CJ. Acute gastrointestinal bleeding: What are the issues the new millennium will resolve? Gastrointest Endosc Clin North Am 2000;10:89-99.
5. Peura DA, Lanza FL, Gostout CJ, et al. The American College of Gastroenterology Bleeding Registry preliminary findings. Am J Gastroenterol 1997;92:924-8.
6. Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol 1997;92:1081-91.
7. Cales P, Desmorat H, Vinel JP, et al. Incidence of large oesophageal varices in patients with cirrhosis: Application to prophylaxis of first bleeding. Gut 1990:1298-1302.
8. Christensen E, Fauerholdt L, Schlichting P, et al. Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effects of prednisone. Gastroenterology 1981;81:944.
9. au and Boston Inter-Hospital Liver Group. The natural history of cirrhosis. II. The influence of alcohol and prior hepatitis on pathology and prognosis. N Engl J Med 1964;271:1173.
10. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800.
11. Garceau AJ, Chalmers TC, the Boston Inter-Hospital Liver Group. The natural history of cirrhosis: I. Survival with esophageal varices. N Engl J Med 1963;268:469-73.
12. Cales P, Desmorat H, Vinel JP, et al. Incidence of large oesophageal varices in patients with cirrhosis: Application to prophylaxis of first bleeding. Gut 1990;31:1298-1302.
13. Gostout CJ. Bleeding esophageal varices. In: Rakel RE, ed. Conn's current therapy. Philadelphia: WB Saunders Co., 1988:457-464.
14. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: A meta-analysis review. Hepatology 1995;22:332-54.
15. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: A prospective multicenter study. N Engl J Med 1988;310:983-9.
16. Kim T, Shijo H, Kokawa H, et al. Risk factors for hemorrhage from gastric fundal varices. Hepatology 1997;25:307-12.
17. Zoli M, Merkel C, Magaloti, et al. Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. Hepatology 1996;24:1047-52.
18. Cales P, Zabotto B, Meskens C, et al. Gastroesophageal endoscopic features in cirrhosis: Observer variability, interassociations, and relationships to hepatic dysfunction. Gastroenterology 1990;98:156-62.
19. Garcia-Tsao G, Groszman RJ, Fisher RL, et al. Portal pressure presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-24.
20. Armonis A, Patch D, Burroughs A. Variceal and portal pressure measurement: Technique and applications. Ital J Gastroenterol 1996;28:272-9.
21. Goff JS. Esophageal varices. Gastrointest Endosc Clin North Am 1994;4:747-71.
22. Jutabha R, Jensen DM. Management of upper gastrointestinal bleeding in the patient with chronic liver disease. Gastrointest Endosc Clin North Am 1996;80:1035-69.
23. Genecin P, Groszman R. Portal hypertension. In: Shiff L, Schiff E, eds. Diseases of the liver, 7th ed, Philadelphia: Lippincott, 1993.
24. Schiff ER. Management of difficult problems in hepatology. Semin Liver Dis 1994;13:317-435.
25. Lee JG, Lieberman D. Complications related to endoscopic hemostasis techniques. Gastrointest Endosc Clin North Am 1996;6:305-21.
26. Teran JC, Imperiale TF, Mullen KD, et al. Primary prophylaxis of variceal bleeding in cirrhosis: A cost-effectiveness analysis. Gastroenterology 1997;112:473-82.
27. Witzel L, Wolbergs E, Merki H. Prophylactic endoscopic sclerotherapy of esophageal varices: A prospective controlled trial. Lancet 1985;1:773-5.
28. Veterans Affair Cooperative Variceal Sclerotherapy Group. Prophylactic sclerotherapy for esophageal varices in alcoholic liver disease: A randomized, single-blind multicenter clinical trial. N Engl J Med 1991;324:1779-84.
29. Piai G, Cipoletta L, Claar M, et al. Prophylactic sclerotherapy of high-risk esophageal varices: Results of a multicentric prospective controlled trial. Hepatology 1988;8:1495-1500.
30. Santangelo WC, Dueno MI, Estes BL, et al. Prophylactic sclerotherapy of large esophageal varices. N Engl J Med 1988;318:814-18.
31. Sauerbruch T, Wotzka R, Kopcke W, et al. Prophylactic sclerotherapy before the first episode of variceal hemorrhage in patients with cirrhosis. N Engl J Med 1988;319:8-14.
32. Triger DR, Smart HL, Hosking SW, et al. Prophylactic sclerotherapy for esophageal varices: Long term results of a single center trial. Hepatology 1991;13:117-23.
33. de Francis R, Primignani M, Arcidiacono PG, et al. Prophylactic sclerotherapy (ST) in high-risk cirrhotics selected by endoscopic criteria. A multicenter randomized controlled trial. Gastroenterology 1991;101:1087-93.
34. Kishimoto H, Sakai M, Kajiyama T, et al. Clinical trial of prophylactic endoscopic variceal ligation for esophageal varices. J Gastroenterol 1997;32:6-11.
35. Przemioslo R, McNair ANB, Williams R. Oesophageal varices: Prophylactic treatment by endoscopic banding ligation prior to index bleed. Eur J Gastroenterol Hepatol 1996;8:329-31.
36. Pagliaro L, D'Amico G, Sorensen TIA, et al. Prevention of first bleeding in cirrhosis: A meta-analysis of randomized trials of non-surgical treatment. Ann Intern Med 1992;117:59-70.
37. Merkel C, Marin R, Enzo E, et al. Randomized trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP). Lancet 1996;348:1677-81.
38. Pascal JP, Cales P, and Multicenter Study Group. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987;317:856-61.
39. Andreani T, Poupon RE, Balkau B, et al. Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: Results of a controlled trial comparing propranolol, endoscopic sclerotherapy, and placebo. Hepatology 1990;12:1412-9.
40. Prova Study Group. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy propranolol or both in cirrhotic patients: A randomized multicenter trial. Hepatology 1991;14:1016-24.
41. Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Engl J Med 1991;324:1532-8.
42. Cello JP, Ring EJ, Olcott EW, et al. Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial. Ann Intern Med 1997;126:858-65.
43. Stiegemann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992;326:1527-32.
44. Hou MC, Liu HC, Kuo BIT, et al. Comparison of endoscopic variceal injection sclerotherapy and ligation for the treatment of esophageal variceal hemorrhage: A prospective randomized trial. Hepatology 1995;21:1517-22.
45. Lo GH, Lai KH, Cheng JS, et al. A prospective randomized trial of sclerotherapy versus ligation in the management of bleeding esophageal varices. Hepatology 1995;22:466-71.
46. Iwas H, Suga S, Shimada M, et al. Eleven-year survey of safety and efficacy of endoscopic injection sclerotherapy using 2% sodium tetradecyl sulfate and contrast medium. J Clin Gastroenterol 1996;22:58-65.
47. Kiviniemi H, Makela J, Haukipuro K, et al. Injection sclerotherapy for oesophageal varices: A ten-year experience. Hepato-Gastroenterology 1995;42:546-50.
48. Besson I, Ingrand P, Person B, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995;333:555-60.
49. Primignani M, Andreoni B, Carpinelli L, et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: A randomized double-blind placebo-controlled multicenter trial. Hepatology 1995;21:1322-27.
50. Copenhagen Esophageal Varices Sclerotherapy Project. Sclerotherapy after first variceal hemorrhage in cirrhosis: A randomized multicenter trial. N Engl J Med 1984;311:1594-1600.
51. Ink O, Martin T, Poynard T, et al. Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter randomized trial. Hepatology 1992;16:912-9.
52. Lo GH, Lai KH, Cheng JS, et al. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology 1997;25:1101-4.
53. Saeed ZA, Stiegemann GV, Ramirez FC, et al. Endoscopic variceal ligation is superior to combined ligation and sclerotherapy for esophageal varices: A multicenter prospective randomized trial. Hepatology 1997;25:71-4.
54. Laine L, El-Newihi HM, Migikovsky B, et al. Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med 1993;119:1-7.
55. Gimson AES, Ramage JK, Panos MZ, et al. Randomized trial of variceal banding ligation versus injection sclerotherapy for bleeding esophageal varices. Lancet 1993;342:391-4.
56. Law AW, Gales MA. Octreotide or vasopressin for bleeding esophageal varices. Ann Pharm 1997;31:237-8.
57. Feu F, Ruiz del Arbol L, Banares R, et al. Double-blind randomized control trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology 1996;111:1291-9.
58. Iwao T, Toyonaga A, Oho K, et al. Effects of vasopressin on esophageal varices blood flow in patients with cirrhosis: Comparisons with the effects on portal vein and superior mesenteric artery blood flow. J Hepatol 1996;25:491-7.
59. Escorcell A, Feu F, Bordas JM, et al. Effects of isosorbide-5-mononitrate on variceal pressure and splanchnic hemodynamics in patients with cirrhosis. J Hepatol 1996;24:423-9.
60. Sugano S, Suzuki T, Nishio M, et al. Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis. Dig Dis Sci 1997;42:529-35.
61. Shields R, Jenkins SA, Baxter JN, et al. A prospective randomized controlled trial comparing the efficacy of somatostatin with injection sclerotherapy in the control of bleeding esophageal varices. J Hepatol 1992;15:128-37.
62. Sung JYJ, Chung SCS, Lai CW, et al. Octreotide infusion or emergency sclerotherapy for variceal hemorrhage. Lancet 1993;342:637-41.
63. Fogel MR, Knauer CM, Andres LL, et al. Continuous intravenous vasopressin in active upper gastrointestinal bleeding: A placebo controlled trial. Ann Intern Med 1982;96:565-9.
64. Merigan TP, Plotkin GR, Davidson CS. Effect of intravenously administered posterior pituitary extract on hemorrhage from bleeding esophageal varices. N Engl J Med 1962;266:134.
65. Teres J, Planas R, Panes J, et al. Vasopressin/nitroglycerin infusion versus esophageal tamponade in the treatment of acute variceal bleeding. A randomized controlled trial. Hepatology 1990;11:964-8.
66. Jaramillo JL, de la Mata M, Mino G, et al. Somatostatin versus Sengstaken balloon tamponade for primary hemostasis of bleeding esophageal varices: A randomized pilot study. J Hepatol 1991;12:100-5.
67. Averginos A, Klonis C, Rekoumis G, et al. A prospective randomized trial comparing somatostatin balloon tamponade and the combination of both methods in the management of acute variceal hemorrhage. J Hepatol 1991;13:78-83.
68. Valenzuela JE, Schubert T, Fogel MR, et al. A multicenter randomized double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology 1989;10:958-61.
69. Hwang SJ, Lin HC, Chang CF, et al. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. J Hepatol 1992;16:320-5.
70. Silvain C, Carpentier S, Sauterau D, et al. Terlipressin plus transdermal nitroglycerin versus octreotide in the control of acute bleeding from esophageal varices: A multicenter randomized trial. Hepatology 1993;18:61-5.
71. Jenkins SA, Baxter JN, Corbett W, et al. A prospective randomized controlled trial comparing somatostatin and vasopressin in controlling acute variceal hemorrhage. Br Med J 1985;290:275-8.
72. Burroughs AK, Mccormick PA, Hughes MD, et al. Randomized double-blind placebo-controlled trial of somatostatin for variceal bleeding: Emergency control and prevention of early variceal bleeding. Gastroenterology 1990;99:1388-95.
73. Bernard B, Lebrec D, Mathurin P, et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis. A meta-analysis. Hepatology 1997;25:63-70.
74. Villeneuve JP, Pomier-Layrargues G, Infante-Rivard C, et al. Propranolol for the prevention of recurrent variceal hemorrhage: A controlled trial. Hepatology 1986;6:1239-43.
75. Garden OJ, Mills PR, Birnie GG, et al. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients: A controlled trial. Gastroenterology 1990;98:185-90.
76. Rossi V, Cales P, Pascal B, et al. Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: Prospective controlled trial of propranolol and sclerotherapy. J Hepatol 1991;12:283-9.
77. Burroughs AK, Jenkins WJ, Sherlock S, et al. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med 1983;309:01539-42.
78. Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996;334:1624-9.
79. Teres J, Bosch J, Bordas JM. Propranolol versus sclerotherapy in preventing variceal rebleeding: A randomized controlled trial. Gastroenterology 1993;105:1508-14.
80. Westaby D, Polson RJ, Gimson AES, et al. A controlled trial of oral propranolol compared with injection sclerotherapy for long term management of variceal bleeding. Hepatology 1990;11:353-9.
81. Fleig WF, Stange EF, Hunecke R, et al. Prevention of recurrent bleeding in cirrhosis with recent variceal hemorrhage. A prospective randomized comparison of propranolol and sclerotherapy. Hepatology 1987;7:355-61.
82. Alexandrino PT, Alces MM, Correia JP. Propranolol or endoscopic sclerotherapy for the prevention of recurrence of variceal bleeding: A prospective randomized controlled trial. J Hepatol 1988;7:175-85.
83. Vinel JP, Lamouliate H, Cales P, et al. Propranolol reduces the rebleeding rate during endoscopic sclerotherapy before variceal obliteration. Gastroenterology 1992;102:1760-3.
84. Avgerinos A, Rekoumis G, Klonis C, et al. Propranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy: A randomized controlled trial. J Hepatol 1993;19:301-11.
85. Vickers C, Rhodes J, Chesner I, et al. Prevention of rebleeding from esophageal varices: Two year follow-up of a prospective controlled trial of propranolol in addition to sclerotherapy. J Hepatol 1994;21:81-7.
86. Acharya KS, Dasarthy S, Saksena S, et al. A prospective randomized study to evaluate propranolol in patients undergoing long-term endoscopic sclerotherapy. J Hepatol 1993;19:291-300.
87. American Society for Gastrointestinal Endoscopy. The role of endoscopic therapy in the management of variceal hemorrhage. Gastrointest Endosc 1998;48:697-8.
88. Brown RS, Lake JR. Transjugular intrahepatic shunt as a form of treatment for portal hypertension: Indications and contra-indications. Adv Intern Med 1997;42:485-504.
89. Rossle M, Deibert P, Haag K, et al. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997;349:1043-9.
90. Sanyal AJ, Freedman AM, Luketic VA, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997;112:889-98.
91. Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Intern Med 1997;126:849-57.
92. Cabrera J, Maynar M, Granados R, et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996;110:832-9.
93. La Berge JM, Somberg KA, Lake JR, et al. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding. Results in 90 patients. Gastroenterology 1995;108:1143-51.
94. Rossle M, Haag K, Ochs A, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994;330:165-71.
95. Henderson JM, Gilmore GT, Hooks MA, et al. Selective shunt in the management of variceal bleeding in the era of liver transplantation. Ann Surg 1992;216:248-55.
96. Grace ND, Conn HO, Resnick RH, et al. Distal splenorenal versus portal-systemic shunts after hemorrhage from varices: A randomized controlled trial. Hepatology 1988;8:1475-81.
97. Reynolds RB, Donovan AJ, Mikkelsen WP, et al. Results of a 12-year randomized trial of portocaval shunt in patients with alcoholic liver disease and bleeding varices. Gastroenterology 1981;80:1005-11.